{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:38:59Z","timestamp":1794591539610,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The role of microglia in the amyloid cascade of Alzheimer\u2019s disease (AD) is debated due to conflicting findings. Using a genetic and a pharmacological approach we demonstrate that depletion of microglia before amyloid-\u03b2 (A\u03b2) plaque deposition, leads to a reduction in plaque numbers and neuritic dystrophy, confirming their role in plaque initiation. Transplanting human microglia restores A\u03b2 plaque formation. While microglia depletion reduces insoluble A\u03b2 levels, soluble A\u03b2 concentrations stay consistent, challenging the view that microglia clear A\u03b2. In later stages, microglial depletion decreases plaque compaction and increases neuritic dystrophy, suggesting a protective role. Human microglia with the\n                    <jats:italic>TREM2<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>R47H\/R47H<\/jats:italic>\n                    <\/jats:sup>\n                    mutation exacerbate plaque pathology, emphasizing the importance of non-reactive microglia in the initiation of the amyloid cascade. Adaptive immune depletion (\n                    <jats:italic>Rag2<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>-\/-<\/jats:italic>\n                    <\/jats:sup>\n                    ) does not affect microglia\u2019s impact on plaque formation. These findings clarify conflicting reports, identifying microglia as key drivers of amyloid pathology, and raise questions about optimal therapeutic strategies for AD.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-54779-w","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T16:56:34Z","timestamp":1733417794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer\u2019s Disease"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-3669","authenticated-orcid":false,"given":"N\u00f3ra","family":"Balig\u00e1cs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-2432","authenticated-orcid":false,"given":"Giulia","family":"Albertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-772X","authenticated-orcid":false,"given":"Sarah C.","family":"Borrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Serneels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-557X","authenticated-orcid":false,"given":"Clare","family":"Pridans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Balusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-5819","authenticated-orcid":false,"given":"Bart","family":"De Strooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"54779_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"54779_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper, B. & Karran, E. The cellular phase of Alzheimer\u2019s disease. Cell 164, 603\u2013615 (2016).","journal-title":"Cell"},{"key":"54779_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s44318-024-00057-w","volume":"43","author":"B De Strooper","year":"2024","unstructured":"De Strooper, B. & Karran, E. New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of \u03b3-secretases. EMBO J. 43, 887\u2013903 (2024).","journal-title":"EMBO J."},{"key":"54779_CR4","doi-asserted-by":"crossref","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s Disease. N Eng. J. Med. 388, 9-21 (2023).","DOI":"10.1056\/NEJMoa2212948"},{"key":"54779_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"54779_CR6","doi-asserted-by":"crossref","unstructured":"Karlsson, I. K. et al. Measuring heritable contributions to Alzheimer\u2019s disease: polygenic risk score analysis with twins. Brain Commun. 4, fcab308 (2022).","DOI":"10.1093\/braincomms\/fcab308"},{"key":"54779_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.abb8575","volume":"370","author":"A Sierksma","year":"2020","unstructured":"Sierksma, A., Escott-Price, V. & De Strooper, B. Translating genetic risk of Alzheimer\u2019s disease into mechanistic insight and drug targets. Science 370, 61\u201366 (2020).","journal-title":"Science"},{"key":"54779_CR8","doi-asserted-by":"crossref","unstructured":"Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 1\u221212 (2017).","DOI":"10.1186\/s13024-017-0184-x"},{"key":"54779_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska, A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173, 1073\u20131081 (2018).","journal-title":"Cell"},{"key":"54779_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch, C. M. & Goate, A. M. Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43\u201351 (2015).","journal-title":"Biol. Psychiatry"},{"key":"54779_CR11","doi-asserted-by":"crossref","unstructured":"Zhao, R., Hu, W., Tsai, J., Li, W. & Gan, W. B. Microglia limit the expansion of \u03b2-amyloid plaques in a mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 12, 1\u221211 (2017).","DOI":"10.1186\/s13024-017-0188-6"},{"key":"54779_CR12","doi-asserted-by":"crossref","unstructured":"Fruhw\u00fcrth, S., Zetterberg, H. & Paludan, S. R. Microglia and amyloid plaque formation in Alzheimer\u2019s disease \u2013 Evidence, possible mechanisms, and future challenges. J. Neuroimmunol. 390, 578342 (2024).","DOI":"10.1016\/j.jneuroim.2024.578342"},{"key":"54779_CR13","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective \u03b2-amyloid clearance pathways in aging alzheimer\u2019s disease mice. J. Neurosci. 28, 8354\u20138360 (2008).","journal-title":"J. Neurosci."},{"key":"54779_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block, M. L., Zecca, L. & Hong, J. S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57\u201369 (2007).","journal-title":"Nat. Rev. Neurosci."},{"key":"54779_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41593-021-00951-0","volume":"25","author":"P d\u2019Errico","year":"2022","unstructured":"d\u2019Errico, P. et al. Microglia contribute to the propagation of A\u03b2 into unaffected brain tissue. Nat. Neurosci. 25, 20\u201325 (2022).","journal-title":"Nat. Neurosci."},{"key":"54779_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11674-z","volume":"10","author":"E Spangenberg","year":"2019","unstructured":"Spangenberg, E. et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer\u2019s disease model. Nat. Commun. 10, 1\u201321 (2019).","journal-title":"Nat. Commun."},{"key":"54779_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s Disease. Cell 169, 1276\u20131290.e17 (2017).","journal-title":"Cell"},{"key":"54779_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio, C. et al. The major risk factors for alzheimer\u2019s disease: age, sex, and genes modulate the microglia response to A\u03b2 Plaques. Cell Rep. 27, 1293\u20131306.e6 (2019).","journal-title":"Cell Rep."},{"key":"54779_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566\u2013581.e9 (2017).","journal-title":"Immunity"},{"key":"54779_CR20","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41593-024-01600-y","volume":"27","author":"R Mancuso","year":"2024","unstructured":"Mancuso, R. et al. Xenografted human microglia display diverse transcriptomic states in response to Alzheimer\u2019s disease-related amyloid-\u03b2 pathology. Nat. Neurosci. 27, 886\u2013900 (2024).","journal-title":"Nat. Neurosci."},{"key":"54779_CR21","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1016\/j.cell.2023.08.037","volume":"186","author":"N Sun","year":"2023","unstructured":"Sun, N. et al. Human microglial state dynamics in Alzheimer\u2019s disease progression. Cell 186, 4386\u20134403.e29 (2023).","journal-title":"Cell"},{"key":"54779_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11053-8","volume":"10","author":"R Rojo","year":"2019","unstructured":"Rojo, R. et al. Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat. Commun. 10, 1\u201317 (2019).","journal-title":"Nat. Commun."},{"key":"54779_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuron.2014.02.040","volume":"82","author":"MRP Elmore","year":"2014","unstructured":"Elmore, M. R. P. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380\u2013397 (2014).","journal-title":"Neuron"},{"key":"54779_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0244-x","volume":"13","author":"J Sosna","year":"2018","unstructured":"Sosna, J. et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 13, 1\u201311 (2018).","journal-title":"Mol. Neurodegener."},{"key":"54779_CR25","doi-asserted-by":"crossref","unstructured":"Kiani Shabestari, S. et al. Absence of microglia promotes diverse pathologies and early lethality in Alzheimer\u2019s disease mice. Cell Rep. 39, 1\u201320 (2022).","DOI":"10.1016\/j.celrep.2022.110961"},{"key":"54779_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/brain\/aww016","volume":"139","author":"EE Spangenberg","year":"2016","unstructured":"Spangenberg, E. E. et al. Eliminating microglia in Alzheimer\u2019s mice prevents neuronal loss without modulating amyloid-\u03b2 pathology. Brain 139, 1265\u20131281 (2016).","journal-title":"Brain"},{"key":"54779_CR27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/brain\/awv379","volume":"139","author":"A Olmos-Alonso","year":"2016","unstructured":"Olmos-Alonso, A. et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer\u2019s-like pathology. Brain 139, 891\u2013907 (2016).","journal-title":"Brain"},{"key":"54779_CR28","doi-asserted-by":"crossref","unstructured":"Clayton, K. et al. Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol. Neurodegener. 16, 1\u221216 (2021).","DOI":"10.1186\/s13024-021-00440-9"},{"key":"54779_CR29","doi-asserted-by":"crossref","unstructured":"Romero-Molina, C. et al. Should we open fire on microglia? Depletion models as tools to elucidate microglial role in health and alzheimer\u2019s disease. Int. J. Mol. Sci. 22, 9734 (2021).","DOI":"10.3390\/ijms22189734"},{"key":"54779_CR30","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.immuni.2022.10.016","volume":"55","author":"X Chen","year":"2022","unstructured":"Chen, X. & Holtzman, D. M. Emerging roles of innate and adaptive immunity in Alzheimer\u2019s disease. Immunity 55, 2236\u20132254 (2022).","journal-title":"Immunity"},{"key":"54779_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-2009-1015","volume":"17","author":"A Larbi","year":"2009","unstructured":"Larbi, A. et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 17, 91\u2013103 (2009).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"54779_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neurobiolaging.2014.08.008","volume":"36","author":"G Lueg","year":"2015","unstructured":"Lueg, G. et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer\u2019s disease. Neurobiol. Aging 36, 81\u201389 (2015).","journal-title":"Neurobiol. Aging"},{"key":"54779_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"D Gate","year":"2020","unstructured":"Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature 577, 399\u2013404 (2020).","journal-title":"Nature"},{"key":"54779_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","volume":"68","author":"Y Shinkai","year":"1992","unstructured":"Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855\u2013867 (1992).","journal-title":"Cell"},{"key":"54779_CR35","doi-asserted-by":"publisher","first-page":"E1316","DOI":"10.1073\/pnas.1525466113","volume":"113","author":"SE Marsh","year":"2016","unstructured":"Marsh, S. E. et al. The adaptive immune system restrains Alzheimer\u2019s disease pathogenesis by modulating microglial function. Proc. Natl Acad. Sci. USA 113, E1316\u2013E1325 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54779_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40478-015-0251-x","volume":"3","author":"C Sp\u00e4ni","year":"2015","unstructured":"Sp\u00e4ni, C. et al. Reduced \u03b2-amyloid pathology in an APP transgenic mouse model of Alzheimer\u2019s disease lacking functional B and T cells. Acta Neuropathol. Commun. 3, 71 (2015).","journal-title":"Acta Neuropathol. Commun."},{"key":"54779_CR37","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546\u20132561 (2019).","journal-title":"J. Exp. Med."},{"key":"54779_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s41593-019-0525-x","volume":"22","author":"R Mancuso","year":"2019","unstructured":"Mancuso, R. et al. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat. Neurosci. 22, 2111\u20132116 (2019).","journal-title":"Nat. Neurosci."},{"key":"54779_CR39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41596-020-00447-4","volume":"16","author":"N Fattorelli","year":"2021","unstructured":"Fattorelli, N. et al. Stem-cell-derived human microglia transplanted into mouse brain to study human disease. Nat. Protoc. 16, 1013\u20131033 (2021).","journal-title":"Nat. Protoc."},{"key":"54779_CR40","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales, K. R. et al. Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 96, 15233\u201315238 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54779_CR41","doi-asserted-by":"crossref","unstructured":"Eskandari-Sedighi, G. & Blurton-Jones, M. Microglial APOE4: more is less and less is more. Mol. Neurodegener. 18, 99 (2023).","DOI":"10.1186\/s13024-023-00693-6"},{"key":"54779_CR42","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","volume":"26","author":"Q Xu","year":"2006","unstructured":"Xu, Q. et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985\u20134994 (2006).","journal-title":"J. Neurosci."},{"key":"54779_CR43","first-page":"453","volume":"15","author":"C Claes","year":"2019","unstructured":"Claes, C. et al. Human stem cell\u2013derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2. Alzheimer\u2019s. Dementia 15, 453\u2013464 (2019).","journal-title":"Dementia"},{"key":"54779_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson, T. et al. Variant of TREM2 Associated with the Risk of Alzheimer\u2019s Disease. N. Engl. J. Med. 368, 107\u2013116 (2013).","journal-title":"N. Engl. J. Med."},{"key":"54779_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro, R. et al. TREM2 variants in AD. N. Engl. J. Med. 368, 117\u2013127 (2013).","journal-title":"N. Engl. J. Med."},{"key":"54779_CR46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160, 1061\u20131071 (2015).","journal-title":"Cell"},{"key":"54779_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.20171529","volume":"215","author":"WM Song","year":"2018","unstructured":"Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215, 745\u2013760 (2018).","journal-title":"J. Exp. Med."},{"key":"54779_CR48","doi-asserted-by":"crossref","unstructured":"Wood, J. I. et al. Plaque contact and unimpaired Trem2 is required for the microglial response to amyloid pathology. Cell Rep. 41, 1\u201313 (2022).","DOI":"10.1016\/j.celrep.2022.111686"},{"key":"54779_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer\u2019s disease. Nat. Med. 26, 131\u2013142 (2020).","journal-title":"Nat. Med."},{"key":"54779_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/glia.24105","volume":"70","author":"CM Henningfield","year":"2022","unstructured":"Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E. & Green, K. N. Microglia-specific ApoE knock-out does not alter Alzheimer\u2019s disease plaque pathogenesis or gene expression. Glia 70, 287\u2013302 (2022).","journal-title":"Glia"},{"key":"54779_CR51","doi-asserted-by":"crossref","unstructured":"Preman, P. et al. APOE from astrocytes restores Alzheimer\u2019s A\u03b2-pathology and DAM-like responses in APOE deficient microglia. EMBO Mol. Med. (online ahead of print) 1\u201329 (2024).","DOI":"10.1038\/s44321-024-00162-7"},{"key":"54779_CR52","doi-asserted-by":"crossref","unstructured":"Kaji, S. et al. Apolipoprotein E aggregation in microglia initiates Alzheimer\u2019s disease pathology by seeding \u03b2-amyloidosis. Immunity 57, 2651\u22122668 (2024).","DOI":"10.1016\/j.immuni.2024.09.014"},{"key":"54779_CR53","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1126\/science.abp9556","volume":"381","author":"S Balusu","year":"2023","unstructured":"Balusu, S. et al. MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer\u2019s disease. Science 381, 1176\u20131182 (2023).","journal-title":"Science"},{"key":"54779_CR54","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1073\/pnas.94.15.7942","volume":"94","author":"A Lomakin","year":"1997","unstructured":"Lomakin, A., Teplow, D. B., Kirschner, D. A. & Benedeki, G. B. Kinetic theory of fibrillogenesis of amyloid \u03b2-protein. Proc. Natl Acad. Sci. USA 94, 7942\u20137947 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54779_CR55","doi-asserted-by":"publisher","first-page":"8972","DOI":"10.1021\/bi9904149","volume":"38","author":"JD Harper","year":"1999","unstructured":"Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Assembly of A\u03b2 amyloid protofibrils: an in vitro model for a possible early event in Alzheimer\u2019s disease. Biochemistry 38, 8972\u20138980 (1999).","journal-title":"Biochemistry"},{"key":"54779_CR56","doi-asserted-by":"publisher","first-page":"20324","DOI":"10.1073\/pnas.0911281106","volume":"106","author":"X Hu","year":"2009","unstructured":"Hu, X. et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl Acad. Sci. USA 106, 20324\u201320329 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54779_CR57","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1073\/pnas.0904532106","volume":"107","author":"RP Friedrich","year":"2010","unstructured":"Friedrich, R. P. et al. Mechanism of amyloid plaque formation suggests an intracellular basis of A\u03b2 pathogenicity. Proc. Natl Acad. Sci. USA 107, 1942\u20131947 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54779_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen, N. et al. Cerebrospinal Fluid-Amyloid (1-42) in Alzheimer disease differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673\u2013680 (1999).","journal-title":"Arch. Neurol."},{"key":"54779_CR59","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF A\u00df 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652\u2013656 (2003).","journal-title":"Neurology"},{"key":"54779_CR60","doi-asserted-by":"publisher","first-page":"32301","DOI":"10.1074\/jbc.274.45.32301","volume":"274","author":"H Chung","year":"1999","unstructured":"Chung, H., Brazil, M. I., Thwe Soe, T. & Maxfield, F. R. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer\u2019s amyloid-peptide by microglial cells. J. Biol. Chem. 274, 32301\u201332308 (1999).","journal-title":"J. Biol. Chem."},{"key":"54779_CR61","doi-asserted-by":"crossref","unstructured":"Frackowiak, J. et al. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce \u03b2-amyloid fibrils. Acta Neuropathol. 84, 225\u2013233 .","DOI":"10.1007\/BF00227813"},{"key":"54779_CR62","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/glia.23074","volume":"64","author":"SH Baik","year":"2016","unstructured":"Baik, S. H., Kang, S., Son, S. M. & Mook-Jung, I. Microglia contributes to plaque growth by cell death due to uptake of amyloid \u03b2 in the brain of Alzheimer\u2019s disease mouse model. Glia 64, 2274\u20132290 (2016).","journal-title":"Glia"},{"key":"54779_CR63","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.15252\/embr.201643411","volume":"18","author":"S Claus","year":"2017","unstructured":"Claus, S. et al. Cellular mechanism of fibril formation from serum amyloid A1 protein. EMBO Rep. 18, 1352\u20131366 (2017).","journal-title":"EMBO Rep."},{"key":"54779_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13506120601116575","volume":"14","author":"N Magy","year":"2007","unstructured":"Magy, N., Benson, M. D., Liepnieks, J. J. & Kluve-Beckerman, B. Cellular events associated with the initial phase of AA amyloidogenesis: Insights from a human monocyte model. Amyloid 14, 51\u201363 (2007).","journal-title":"Amyloid"},{"key":"54779_CR65","doi-asserted-by":"crossref","unstructured":"Cadiz, M. P. et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J. Exp. Med. 221, e20231363 (2024).","DOI":"10.1084\/jem.20231363"},{"key":"54779_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.07.003","volume":"61","author":"EE Spangenberg","year":"2017","unstructured":"Spangenberg, E. E. & Green, K. N. Inflammation in Alzheimer\u2019s disease: Lessons learned from microglia-depletion models. Brain Behav. Immun. 61, 1\u201311 (2017).","journal-title":"Brain Behav. Immun."},{"key":"54779_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157\u2013172 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"54779_CR68","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito, T. et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 17, 661\u2013663 (2014).","journal-title":"Nat. Neurosci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54779-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54779-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54779-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T18:01:31Z","timestamp":1733421691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54779-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54779"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54779-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.06.606783","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.D.S. has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies and is now consultant to Muna Therapeutics. B.D.S is a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10634"}}